Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 78,900 shares, an increase of 54.1% from the October 15th total of 51,200 shares. Currently, 1.3% of the company’s shares are sold short. Based on an average trading volume of 123,300 shares, the short-interest ratio is presently 0.6 days.

Adial Pharmaceuticals Stock Performance

Shares of NASDAQ ADIL opened at $1.14 on Friday. Adial Pharmaceuticals has a fifty-two week low of $0.77 and a fifty-two week high of $4.17. The company’s 50 day simple moving average is $1.02 and its 200 day simple moving average is $1.14.

Adial Pharmaceuticals (NASDAQ:ADIL) last issued its earnings results on Tuesday, August 13th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.20). On average, research analysts anticipate that Adial Pharmaceuticals will post -1.79 EPS for the current year.

Institutional Investors Weigh In On Adial Pharmaceuticals

An institutional investor recently bought a new position in Adial Pharmaceuticals stock. Virtu Financial LLC bought a new position in shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund bought 20,469 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned 0.48% of Adial Pharmaceuticals at the end of the most recent quarter. 16.41% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Rodman & Renshaw assumed coverage on Adial Pharmaceuticals in a report on Thursday. They set a “buy” rating and a $8.00 price objective for the company.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.